首页 文献索引 SCI期刊 AI助手
条件筛选
相关性 最新发表 最早发表
全文 标题 期刊 作者
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
模糊 精准
{{tag.shortname||tag.name}}:{{getFilterLabel(field)}} Clear All
Einar K Rofstad,Else-Beate M Ruud,Berit Mathiesen et al. Einar K Rofstad et al.
The aim of this preclinical study was to investigate whether tumor radiocurability may be associated with IFP through hypoxia-independent mechanisms.
Einar K Rofstad,Jon-Vidar Gaustad,Kjetil G Brurberg et al. Einar K Rofstad et al.
The main aims of this study were to investigate whether tumor radiocurability may be associated with IFP and, if so, to identify possible mechanisms. Human melanoma xenografts transplanted intradermally or in window chamber preparations in BALB/c nu/nu mice were used as preclinical tumor models....Therefore, the observed association between tumor radiocurability and IFP was most likely an indirect consequence of a strong relationship between IFP and the fraction of acutely hypoxic cells.
Nicole Wiedenmann,David Valdecanas,Nancy Hunter et al. Nicole Wiedenmann et al.
Purpose: 130-nm albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free albumin-bound paclitaxel, designed to avoid solvent-related toxicity. Nab-paclitaxel has been successfully introduced into the clinic but i...
Luka Milas,Zhen Fan,Nicolaus H Andratschke et al. Luka Milas et al.
Results: Our studies showed that high levels of EGFR were associated with decreased tumor radiocurability of murine carcinomas. The causal role of EGFR in mediating cellular resistance to RT was demonstrated by transfecting the EGFR cDNA into the cells with low levels of EGFR.
Simona Kranjc,Maja Cemazar,Alenka Grosel et al. Simona Kranjc et al.
Also, the tumor radiocurability of this combined treatment was significantly enhanced, compared to irradiated tumors (enhancement factor; EF = 1.6) and to tumors treated with cisplatin and irradiation (EF = 1.4).
Luka Milas,Kathryn A Mason,Nancy Hunter et al. Luka Milas et al.
Conclusion: PG-TXL dramatically potentiated tumor radiocurability after single-dose or fractionated irradiation without affecting acute normal tissue injury.
S Nasu,K K Ang,Z Fan et al. S Nasu et al.
Conclusion: The data presented here demonstrate that C225 can increase tumor radiocurability and delay the appearance of recurrences of tumors not cured by radiation treatment.
L Milas,T Fujii,N Hunter et al. L Milas et al.
Although gemcitabine reduced the radiation tumor control dose at all administration times used, the greatest enhancement of tumor radiocurability occurred when gemcitabine was administered 24 h before irradiation (dose modification factor of 1.54).
R R Weichselbaum,J B Little R R Weichselbaum
We also have examined how the repair of potentially lethal damage may alter the therapeutic ratio by altering tumor radiocurability and normal tissue tolerance.
L J Peters,W Brock,T Johnson L J Peters
Several predictors of tumor radiocurability are already integrated into clinical practice, e.g., tumor size, gross morphologic features (i.e., infiltrative or exophytic), histologic type, and grade. These are relatively imprecise, however, and none is specific.
耗时 0.08576 秒,为您在 48229835 条记录里面共找到 20 篇文章 [XML]